Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

Table 3 Adjusted odds ratios for risk of hospitalization by G-CSF

Variable	Neutropenia-Related		All-Cause
	Narrow Definition	Broad Definition
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Prophylactic pegfilgrastim (vs. prophylactic filgrastim)	0.43 (0.16–1.13)	0.38 (0.24–0.59)	0.50 (0.35–0.72)
Age	1.01 (0.99–1.03)	1.00 (0.99–1.01)	1.00 (1.00–1.01)
Gender male	0.79 (0.39–1.59)	1.40 (1.03–1.90)	0.94 (0.94–1.18)
Baseline Quan-Charlson comorbidity score	1.02 (0.96–1.14)	1.09 (1.04–1.15)	1.07 (1.03–1.11)
Prior anemia	0.95 (0.57–1.58)	1.30 (1.02–1.66)	1.34 (1.13–1.60)
Breast cancer^*	0.28 (0.14–0.56)	0.44 (0.32–0.61)	0.47 (0.38–0.59)
Lung cancer^*	0.22 (0.07–0.64)	0.54 (0.37–0.77)	0.84 (0.65–1.08)
Number of myelosuppressive chemotherapy agents^†	2.28 (1.33–3.89)	0.86 (0.68–1.07)	0.95 (0.81–1.12)

All odds ratios (OR) are adjusted for the other variables listed.
^* Compared to NHL, ovarian cancer, and colorectal cancer.
^† Myelosuppressive chemotherapy agent was defined as one of the following agents: bendamustine, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, hydroxyurea, idarubicin, ifosfamide, irinotecan, ixabepilone, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed disodium, procarbazine, temozolomide, teniposide, thiotepa, or topotecan.

ISSN: 1471-2407